Casirivimab and Imdevimab antibody cocktail resulted in lesser requirement of mechanical ventilation and high-flow oxygen with no deaths as compared to the controls in symptomatic Covid-19 patients. The non-vaccinated patients who received this antibody cocktail did not require mechanical ventilation and those who were fully immunized seldom entailed high-flow oxygen. Casirivimab and Imdevimab treatment regimen is clinically beneficial for high risk COVID19 patients.